{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:11:47Z","timestamp":1771474307552,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7244361"],"award-info":[{"award-number":["7244361"]}]},{"name":"Beijing Natural Science Foundation","award":["7151005"],"award-info":[{"award-number":["7151005"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81761128021, 81771452, 82171507"],"award-info":[{"award-number":["81761128021, 81771452, 82171507"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clozapine is an off-label drug used in most countries to prevent suicide in individuals with schizophrenia. However, few studies have reported real-world prescription practices. This study aimed to explore the association between a history of suicidal behavior and clozapine prescribing during eight weeks of hospitalization for individuals with early-stage schizophrenia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This observational cohort study used routine health data collected from a mental health hospital in Beijing, China. The study included 1057 inpatients who had schizophrenia onset within 3 years. History of suicidal behavior was coded from reviewing medical notes according to the Columbia Suicide Severity Rating Scale. Information on antipsychotic use during hospitalization was extracted from the prescription records. Time to clozapine use was analyzed using Cox regression models adjusted for sociodemographic and clinical covariates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prevalence rates of self-harm, suicidal behavior, and suicide attempt were 12.3%, 7.5%, and 5.4%, respectively. A history of self-harm history was positively associated with clozapine uses upon admission (4.1% vs. 0.8%, exact <jats:italic>p<\/jats:italic>\u2009=\u20090.009). Among those who had not used clozapine and had no clozapine contraindication, A history of suicidal behavior increased the possibility of switch to clozapine within 56 days after admission (Hazard Ratio[95% CI],\u00a06.09[2.08\u201317.83]) or during hospitalization (4.18[1.62\u201310.78]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The use of clozapine for early-stage schizophrenia was more frequent among those with suicidal behavior than among those without suicidal behavior in China, although the drug instructions do not label its use for suicide risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-024-05893-y","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T10:02:08Z","timestamp":1718186528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["History of suicidal behavior and clozapine prescribing among people with schizophrenia in China: a cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Yi","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghui","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baopeng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fude","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Elliot","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"5893_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.psychres.2018.09.038","volume":"270","author":"YS Ko","year":"2018","unstructured":"Ko YS, Tsai H-C, Chi MH, Su C-C, Lee IH, Chen PS, et al. Higher mortality and years of potential life lost of suicide in patients with schizophrenia. Psychiatry Res. 2018;270:531\u20137.","journal-title":"Psychiatry Res"},{"issue":"4","key":"5893_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1192\/bjp.bp.113.139733","volume":"206","author":"MS Ran","year":"2015","unstructured":"Ran MS, Mao WJ, Chan CL, Chen EY, Conwell Y. Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study. Br J Psychiatry. 2015;206(4):283\u20138.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"5893_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2215-0366(20)30004-3","volume":"7","author":"Y Chai","year":"2020","unstructured":"Chai Y, Luo H, Wong GHY, Tang JYM, Lam T-C, Wong ICK, et al. Risk of self-harm after the diagnosis of psychiatric disorders in Hong Kong, 2000-10: a nested case-control study. Lancet Psychiatry. 2020;7(2):135\u201347.","journal-title":"Lancet Psychiatry"},{"key":"5893_CR4","doi-asserted-by":"publisher","first-page":"114330","DOI":"10.1016\/j.psychres.2021.114330","volume":"308","author":"X Liu","year":"2022","unstructured":"Liu X, Wang D, Fan R, Wang R, Xiang H, Yang X, et al. Life expectancy and potential years of life lost for schizophrenia in western China. Psychiatry Res. 2022;308:114330.","journal-title":"Psychiatry Res"},{"key":"5893_CR5","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1017\/S2045796019000313","volume":"29","author":"L Lu","year":"2019","unstructured":"Lu L, Dong M, Zhang L, Zhu XM, Ungvari GS, Ng CH, et al. Prevalence of suicide attempts in individuals with schizophrenia: a meta-analysis of observational studies. Epidemiol Psychiatric Sci. 2019;29:e39.","journal-title":"Epidemiol Psychiatric Sci"},{"issue":"1","key":"5893_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","volume":"60","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: international suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82\u201391.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"5893_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/schbul\/sbaa111","volume":"47","author":"H Taipale","year":"2021","unstructured":"Taipale H, L\u00e4hteenvuo M, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J. Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with Schizophrenia. Schizophr Bull. 2021;47(1):23\u201330.","journal-title":"Schizophr Bull"},{"issue":"10","key":"5893_CR8","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","volume":"174","author":"T Wimberley","year":"2017","unstructured":"Wimberley T, MacCabe JH, Laursen TM, S\u00f8rensen HJ, Astrup A, Horsdal HT, et al. Mortality and self-harm in Association with Clozapine in Treatment-resistant Schizophrenia. Am J Psychiatry. 2017;174(10):990\u20138.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"5893_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/acps.12857","volume":"137","author":"CH Ma","year":"2018","unstructured":"Ma CH, Chang SS, Tsai HJ, Gau SS, Chen IM, Liao SC, et al. Comparative effect of antipsychotics on risk of self-harm among patients with schizophrenia. Acta Psychiatr Scand. 2018;137(4):296\u2013305.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"5893_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/schbul\/sby052","volume":"45","author":"JM Vermeulen","year":"2019","unstructured":"Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with Schizophrenia: a systematic review and Meta-analysis of studies lasting 1.1\u201312.5 years. Schizophr Bull. 2019;45(2):315\u201329.","journal-title":"Schizophr Bull"},{"key":"5893_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ajp.2016.12.008","volume":"26","author":"T Bastiampillai","year":"2017","unstructured":"Bastiampillai T, Tonnu O, Tibrewal P, Dhillon R. Why not clozapine for the patient with schizophrenia at risk of suicide? Asian J Psychiatr. 2017;26:6\u20137.","journal-title":"Asian J Psychiatr"},{"key":"5893_CR12","volume-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2021","unstructured":"American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Third ed. Washington, DC: American Psychiatric Association; 2021.","edition":"Third"},{"key":"5893_CR13","unstructured":"China\u2019s National Commission of Health. Practice guidelines for the treatment of mental disorders Beijing2020 [cited China\u2019s National Commission of Health. http:\/\/www.nhc.gov.cn\/cms-search\/xxgk\/getManuscriptXxgk.htm?id=a1c4397dbf504e1393b3d2f6c263d782."},{"key":"5893_CR14","unstructured":"China\u2019s National Medical Products Administration. The National Medical Products Administration\u2019s Announcement on the labeling changes of clozapine tablets. (2019, No. 64) Beijing2019 [ https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypshmshxdgg\/20190816165101366.html."},{"key":"5893_CR15","volume-title":"Guideline on prevention and treatment of schizophrenia","author":"J Zhao","year":"2015","unstructured":"Zhao J, Shi S. Guideline on prevention and treatment of schizophrenia. second ed. Beijing: Chinese Medical Multimedia; 2015.","edition":"second"},{"issue":"5","key":"5893_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/08039488.2022.2160878","volume":"77","author":"IJ Michelle","year":"2023","unstructured":"Michelle IJ. Antipsychotic prescribing practices for outpatients with schizophrenia and reasons for non-clozapine treatment - data from a Danish quality assessment audit. Nord J Psychiatry. 2023;77(5):481\u201390.","journal-title":"Nord J Psychiatry"},{"key":"5893_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.schres.2020.07.023","volume":"224","author":"JC Williams","year":"2020","unstructured":"Williams JC, Harowitz J, Glover J, Tek C, Srihari V. Systematic review of racial disparities in clozapine prescribing. Schizophr Res. 2020;224:11\u20138.","journal-title":"Schizophr Res"},{"key":"5893_CR18","doi-asserted-by":"crossref","unstructured":"Pandarakalam JP. The art of clozapine therapy and clozaphobia. BMJ. 2019.","DOI":"10.1136\/bmj.l484"},{"issue":"5","key":"5893_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0004867419833166","volume":"53","author":"N Myles","year":"2019","unstructured":"Myles N, Myles H, Xia S, Large M, Bird R, Galletly C, et al. A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. Aust N Z J Psychiatry. 2019;53(5):403\u201312.","journal-title":"Aust N Z J Psychiatry"},{"key":"5893_CR20","doi-asserted-by":"crossref","unstructured":"Rubio JM, Kane JM, Tanskanen A, Tiihonen J, Taipale H. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case\u2013control study in Finland. Lancet Psychiatry. 2024:Online ahead of print.","DOI":"10.1016\/S2215-0366(24)00097-X"},{"key":"5893_CR21","doi-asserted-by":"publisher","unstructured":"Peter M, Nilofar S, Liliana MR, John MK, Christoph UC. Benign ethnic Neutropenia and Clozapine Use: a systematic review of the evidence and treatment recommendations. J Clin Psychiatry. 2016;77(7). https:\/\/doi.org\/10.4088\/JCP.15r10085-16.","DOI":"10.4088\/JCP.15r10085-16"},{"key":"5893_CR22","doi-asserted-by":"crossref","unstructured":"Oloyede E, Blackman G, Whiskey E, Bachmann C, Dzahini O, Shergill S et al. Clozapine haematological monitoring for neutropenia: a global perspective. Epidemiol Psychiatric Sci. 2022;31.","DOI":"10.1017\/S204579602200066X"},{"issue":"3","key":"5893_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/17512433.2023.2183192","volume":"16","author":"JG Leung","year":"2023","unstructured":"Leung JG, Ehret M, Love RC, Cotes RO. Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues. Expert Rev Clin Pharmacol. 2023;16(3):177\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5893_CR24","doi-asserted-by":"crossref","unstructured":"Xu SW, Dong M, Zhang Q, Yang SY, Chen LY, Sim K et al. Clozapine prescription pattern in patients with schizophrenia in Asia: The REAP survey (2016). Psychiatry Res. 2020;287:112271.","DOI":"10.1016\/j.psychres.2019.02.056"},{"issue":"2","key":"5893_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1176\/appi.ajp.157.2.172","volume":"157","author":"R Howard","year":"2000","unstructured":"Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry. 2000;157(2):172\u20138.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"5893_CR26","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266\u201377.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"5893_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"6","key":"5893_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"5893_CR29","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/eip.13046","volume":"15","author":"M Zhu","year":"2021","unstructured":"Zhu M, Ferrara M, Tan W, Shang X, Syed S, Zhang L, et al. Drug-na\u00efve first-episode schizophrenia spectrum disorders: pharmacological treatment practices in inpatient units in Hunan Province, China. Early Interv Psychiatry. 2021;15(4):1010\u20138.","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"5893_CR30","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1192\/j.eurpsy.2021.2258","volume":"65","author":"CH Goh","year":"2022","unstructured":"Goh CH, Huang M-W, Liu Y, Qiu H, Shen S-P, Tang C-H, et al. Risks of all-cause death and completed suicide in patients with schizophrenia\/schizoaffective disorder treated with long-acting injectable or oral antipsychotics: a population-based retrospective cohort study in Taiwan. Eur Psychiatry. 2022;65(1):e5.","journal-title":"Eur Psychiatry"},{"issue":"4","key":"5893_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1521\/suli.2008.38.4.449","volume":"38","author":"J Li","year":"2008","unstructured":"Li J, Ran MS, Hao Y, Zhao Z, Guo Y, Su J, et al. Inpatient suicide in a Chinese psychiatric hospital. Suicide Life Threat Behav. 2008;38(4):449\u201355.","journal-title":"Suicide Life Threat Behav"},{"issue":"1","key":"5893_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/acps.12742","volume":"136","author":"CJ Bachmann","year":"2017","unstructured":"Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37\u201351.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"5893_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","volume":"11","author":"E Wagner","year":"2021","unstructured":"Wagner E, Siafis S, Fernando P, Falkai P, Honer WG, Roh A, et al. Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. Transl Psychiatry. 2021;11(1):487.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"5893_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2215-0366(23)00406-6","volume":"11","author":"The Lancet Psychiatry","year":"2024","unstructured":"The Lancet Psychiatry. Clozapine: past, present, and future. Lancet Psychiatry. 2024;11(1):1.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"5893_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2215-0366(23)00343-7","volume":"11","author":"K Northwood","year":"2024","unstructured":"Northwood K, Myles N, Clark SR, Every-Palmer S, Myles H, Kisely S, et al. Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study. Lancet Psychiatry. 2024;11(1):27\u201335.","journal-title":"Lancet Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05893-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-05893-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-05893-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T10:09:35Z","timestamp":1718186975000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-05893-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5893"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-05893-y","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Boards of the Beijing HuiLongGuan Hospital, Beijing, China. Institutional Review Boards of the Beijing HuiLongGuan Hospital waived the informed consent from the participants because the information was routine medical records according to local regulations. Beijing HuiLongGuan Hospital approved the use of routine electronic medical records data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Hong has received or is planning to receive research funding or consulting fees from Mitsubishi, Your Energy Systems LLC, Neuralstem, Taisho, Heptares, Pfizer, Sound Pharma, Luye Pharma, Takeda, and Regeneron. None was involved in the design, analysis, or outcomes of the study. Other authors declare that the research was conducted without any relationships that could be interpreted as a potential conflict of interest or financial conflict.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"440"}}